Company profile for Zenara Pharma

PharmaCompass
Related CompaniesRelated Companies

About

Our state-of-the-art manufacturing facility at Cherlapally, Hyderabad is designed, equipped and maintained as per latest cGMP norms. The company’s manufacturing facility is fully equipped to manufacture both Solid Orals (Tablets, Capsules) and Oral liquids in various therapeutic categories. Zenara has in-house capability to ensure regulatory compliance in all the markets we operate in. We are constantly strengthening our global supply chain with customers in key markets including United States of America, Europe, Australia, New Zealand, Canada, Far East Asia, GCC (Gulf Cooperation Council), Brazil among others.

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
India
Address
Address
Plot No.83/B, 84 & 87 to 96, Phase - III, IDA Cherlapally, Hyderabad - 500 051
Telephone
Telephone
+91 4027260848
youtube
YouTube
Contact Info
Others

Events

Webinars & Exhibitions

Default Event

CPhI North America

Not Confirmed

envelop Contact Supplier

CPhI North America

Post an Enquiry

Meeting

Digital content read-more

Explore the latest content creation from this company

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214844

FDA
03 Feb 2025

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218205

FDA
21 Aug 2024

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218169

FDA
05 Aug 2024

https://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/biophore-its-subsidiary-zenara-pharma-receive-first-approval-for-cannabidiol-in-india/100251790

HEALTH ET
15 May 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212420

FDA
02 May 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216842

FDA
04 Apr 2023

Drugs in Development

read-more
read-more

Details:

Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.


Lead Product(s): Cannabidiol

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 15, 2023

Biophore CB

01

Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

May 15, 2023

Biophore CB

Details:

Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.


Lead Product(s): Nirmatrelvir,Ritonavir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Paxzen

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Pfizer Inc

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 28, 2022

Biophore CB

02

Details : Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.

Product Name : Paxzen

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

July 28, 2022

Biophore CB

Details:

Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.


Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 08, 2020

Biophore CB

03

Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.

Product Name : Favizen

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 08, 2020

Biophore CB

Details:

Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.


Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Favizen

Study Phase: Approved FDFProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 08, 2020

Biophore CB

04

Details : Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.

Product Name : Favizen

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 08, 2020

Biophore CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Check the inspections & registration from this company

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty